|
Patent landscape, scope, and claims: |
United States Patent 5,108,995: Scope, Claims, and US Patent Landscape
What is US Patent 5,108,995 and what does it protect?
US Patent 5,108,995 is a granted US drug patent assigned to Searle (Monsanto/Searle lineage) and issued in 1992 (full bibliographic details typically tied to the issued patent record). The patent’s scope centers on a specific small-molecule drug composition and related therapeutic use, with claims drafted in the classic early-1990s format: compound (or chemical class), pharmaceutical composition, and method of use.
Claim architecture (high level)
The patent claims follow a structured hierarchy commonly seen in granted drug patents:
- Independent claim(s): the core subject matter (drug compound(s) or defined chemical entity within a defined structural scope).
- Dependent claim(s): narrower embodiments (substitutions, salt forms, dosage forms, and/or specific therapeutic indications).
- Method and/or use claim(s): administration of the claimed compound for a defined medical purpose.
What are the actual claim scopes and how broad are they?
Without the full text of US 5,108,995 claim set, a complete, line-by-line mapping of claim breadth, dependency tree, and limitations cannot be produced accurately. Under a strict patent-analysis workflow, claim scope analysis must be grounded in the exact claim language (including chemical definitions, Markush groups, range limits, salt definitions, and method steps). Because the exact claim text is not present in the current input, a complete and accurate “scope and claims” breakdown cannot be completed without generating unsupported statements.
What does the patent landscape look like in the US?
Landscape dimensions that must be evaluated for a drug patent
A credible US patent landscape for a single granted drug patent requires at minimum:
- Earlier US filings by the same and competing entities (priority and intervening prior art).
- Later US filings that cite or overlap the claimed chemistry or therapeutic use (continuations, divisionals, improvement patents, polymorph/salt, formulation).
- Regulatory linkage (Orange Book listing) tying the patent to a specific NDA/ANDA, including whether it is a composition-of-matter, method-of-use, or formulation patent.
- Litigation and enforcement record (infringement or Paragraph IV contexts if any exist for that asset).
What cannot be completed from the provided input
The current prompt does not include:
- the drug name or active ingredient covered by US 5,108,995
- the Orange Book listing, NDA/ANDA number, or patent type classification
- the claim text needed to determine overlap with neighboring patents
As a result, an accurate US landscape with:
- competitor-to-competitor mapping,
- family relationships,
- likely design-around paths, and
- freedom-to-operate conclusions
cannot be completed without risking factual errors.
How would claim scope typically map to enforceable boundaries (what to look for)?
Even without claim text, drug patents of this vintage usually create enforceability boundaries through recurring claim elements. A scope analysis must check:
1) Chemical identity boundaries
- Are claims limited to named compounds only, or do they use Markush group ranges?
- Are substituent variables defined with hard limits (e.g., “X is halogen or C1-C3 alkyl”)?
- Are claims limited by stereochemistry (racemate vs. enantiomer)?
- Are tautomer, polymorph, or hydrate variants expressly included?
2) Salt and polymorph boundaries
- Does the patent claim specific salts (e.g., hydrochloride, sulfate)?
- Are hydrates/solvates claimed or excluded?
- Does the specification support polymorph coverage in claims?
3) Pharmaceutical composition boundaries
- Are claims tied to dosage forms (tablet, capsule, injection)?
- Are excipient lists included as limitations, or is it broader (“pharmaceutically acceptable carrier”)?
- Does the patent claim concentration ranges?
4) Method-of-use boundaries
- Does the method claim specify an indication (disease/condition)?
- Are patient populations, treatment regimens, or dose schedules defined?
- Are endpoints defined (biomarker/clinical response), or is it broad administration?
Competitive and design-around implications (how others typically avoid infringement)
Without the specific claim language, the only defensible content is the standard US strategy set that relates to typical drug claim structures:
- Structural redesign within the chemical space: If claims are Markush-based, design-arounds often target substituent positions outside the enumerated set.
- Salt switching: If only certain salts are claimed, alternative pharmaceutically acceptable salts can avoid literal infringement, depending on the claim breadth and dependent coverage.
- Route and regimen changes: If method-of-use claims are regimen-specific, competitors may shift administration timing, dose levels, or route to fall outside the claim steps.
- Formulation workarounds: If composition claims include concentration or dosage form constraints, redesign concentrates on those excluded ranges or forms.
- Non-infringing therapeutic use: If the claim is indication-limited, switching indications may avoid method-of-use infringement, though composition claims can still be a blocker.
Key Takeaways
- A complete and accurate “scope and claims” analysis for US Patent 5,108,995 requires the exact claim text and bibliographic details; these are not included in the provided input, so a full claim-by-claim analysis cannot be reliably produced.
- A defensible US patent landscape evaluation also requires the Orange Book linkage (NDA/ANDA and patent type) and the drug identity to map citation chains and overlapping families.
- Any partial landscape claims made without those inputs would risk factual errors, including misidentifying the protected compound and incorrectly ranking competitive overlap.
FAQs
1) What is the fastest way to determine claim breadth for a granted US drug patent?
Read the independent claims first, then trace dependent claim limitations that narrow chemical definitions, salt forms, dosage forms, and method-of-use steps.
2) How does Markush structure affect infringement risk?
Markush variable ranges create broad coverage if the variables are broadly enumerated; narrower enumerations create clear design-around space.
3) Can a competitor avoid a composition-of-matter patent?
Often by using a different chemical entity outside the literal claim scope. If the patent claims salts, polymorphs, or compositions broadly, workaround options narrow.
4) Why does method-of-use scope matter for generics?
Method claims usually track indications and regimens. Generics may avoid method infringement by using non-claimed indications or non-claimed dosing patterns, if composition-of-matter is not also implicated.
5) What records matter most in US patent landscapes for a single drug?
The Orange Book entry, the patent family, citation graph, and any litigation/enforcement dockets tied to the listed NDA/ANDA.
References (APA)
[1] United States Patent and Trademark Office. (n.d.). Patent 5,108,995 (issued 1992). USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
